Publications

• Discovery and Preclinical Profile of Saxagliptin (BMS-477118): A Highly Potent, Long-Acting, Orally Active Dipeptidyl Peptidase IV Inhibitor for the Treatment of Type 2 Diabetes
• An inhibitor of Bcl-2 family proteins induces regression of solid tumours
• Discovery of a Potent Inhibitor of the Antiapoptotic Protein Bcl-xL from NMR and Parallel Synthesis
• Synthesis of Novel Pot...
• The Thermodynamics of Binding, The Medicinal Chemistry of Drug Design and Of Late-Stage Structural Optimization
• NMR-Based Screening of Proteins Containing 13C-Labeled Methyl Groups
• Article 2: An inhibitor of Bcl-2 family proteins induces regression of solid tumours
• Dr. David J. Augeri, PhD Expert Witness/Expert Medicinal Chemist - January 2026.pdf

Pharmaceutical IP Litigation Expert Witness

Specialties & Experience of this Expert Witness

Additional Information

With over 10 years of experience as an expert witness at DJ Augeri Pharma Consulting LLC, I specialize in pharmaceutical patent litigation, specifically in the areas of synthetic organic and medicinal chemistry, drug discovery, and CMC/API process development. I provide critical support for legal clients, offering expert reports, prior art review, claims interpretation, and testimony in U.S. and Canadian courts. My work spans patent infringement, validity, obviousness, and enablement analyses, as well as consulting on ANDA/Hatch-Waxman litigation, with a focus on diabetes and oncology drugs. I am committed to advancing pharmaceutical innovation by combining my expertise in medicinal chemistry, structure–activity relationships, and drug development, from preclinical research to IND submissions. My technical contributions include designing alternative compounds, optimizing drug properties, and overseeing CMC facets of clinical development. I strive to provide high-quality, data-driven insights that meet the highest academic and professional standards for the benefit of my clients and their groundbreaking projects.